Foglietta Myriam, Castella Barbara, Mariani Sara, Coscia Marta, Godio Laura, Ferracini Riccardo, Ruggeri Marina, Muccio Vittorio, Omedé Paola, Palumbo Antonio, Boccadoro Mario, Massaia Massimo
Divisione di Ematologia dell'Università di Torino, Dipartimento di Biotecnologie Molecolari e Scienze della Salute, Italy Laboratorio di Ematologia Oncologica, Centro di Ricerca in Medicina Sperimentale (CeRMS), Italy Azienda Ospedaliera-Universitaria Città della Salute e della Scienza di Torino, Italy.
Divisione di Ematologia dell'Università di Torino, Dipartimento di Biotecnologie Molecolari e Scienze della Salute, Italy Laboratorio di Ematologia Oncologica, Centro di Ricerca in Medicina Sperimentale (CeRMS), Italy.
Haematologica. 2014 Oct;99(10):1605-10. doi: 10.3324/haematol.2014.105866. Epub 2014 Jun 27.
Conflicting data have been reported about the frequency and function of regulatory T cells in multiple myeloma. Most studies have investigated peripheral blood rather than bone marrow Tregs and side-by-side comparisons with bone marrow from healthy donors have still not been made. In this study, we show that regulatory T-cells total count, subset distribution, and expression of chemokine receptors are similar in the bone marrow of myeloma patients and healthy donors. Regulatory T cells are not recruited by myeloma cells in the bone marrow and their counts are unaffected by the tumor burden and the disease status. The diversity of T-cell receptor repertoire is highly preserved ensuring broad reactivity and effective suppressor function. Our results indicate that regulatory T cells may not be the main players of immunological tolerance to myeloma cells under base-line conditions, but their fully preserved immune competence may promote their inadvertent activation and blunt T-cell driven anti-myeloma immune interventions even after myeloma cells have successfully been cleared by chemotherapy.
关于多发性骨髓瘤中调节性T细胞的频率和功能,已有相互矛盾的数据报道。大多数研究调查的是外周血而非骨髓中的调节性T细胞,且尚未与健康供体的骨髓进行并行比较。在本研究中,我们发现骨髓瘤患者骨髓与健康供体骨髓中的调节性T细胞总数、亚群分布及趋化因子受体表达相似。骨髓中的骨髓瘤细胞不会招募调节性T细胞,其数量也不受肿瘤负荷和疾病状态的影响。T细胞受体库的多样性得到高度保留,确保了广泛的反应性和有效的抑制功能。我们的结果表明,在基线条件下,调节性T细胞可能不是对骨髓瘤细胞免疫耐受的主要参与者,但即使骨髓瘤细胞已通过化疗成功清除,其完全保留的免疫能力仍可能促进其意外激活并削弱T细胞驱动的抗骨髓瘤免疫干预。